Molecular Partners Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Molecular Partners kazanç ve gelirin sırasıyla yıllık 16.9% ve 49% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 15.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 48.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.9%

Kazanç büyüme oranı

15.40%

EPS büyüme oranı

Biotechs kazanç büyümesi	23.5%
Gelir büyüme oranı	49.0%
Gelecekteki özkaynak getirisi	48.23%
Analist kapsamı	Low
Son güncelleme	13 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Mar 13

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Sep 10

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Apr 11

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Key Insights Molecular Partners to hold its Annual General Meeting on 17th of April Salary of CHF385.0k is part of CEO...

Analiz Makalesi • Jan 09

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Sep 08

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Jun 23

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

The latest analyst coverage could presage a bad day for Molecular Partners AG ( VTX:MOLN ), with the analysts making...

Analiz Makalesi • Aug 31

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

One thing we could say about the analysts on Molecular Partners AG ( VTX:MOLN ) - they aren't optimistic, having just...

Analiz Makalesi • May 09

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Dec 26

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Shareholders in Molecular Partners AG ( VTX:MOLN ) may be thrilled to learn that the analysts have just delivered a...

Kazanç ve Gelir Büyüme Tahminleri

SWX:MOLN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CHF Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	N/A	-55	-52	-43	2
12/31/2027	31	-23	15	15	4
12/31/2026	6	-55	-36	-21	4
3/31/2026	N/A	-58	-49	-48	N/A
12/31/2025	N/A	-62	-52	-51	N/A
9/30/2025	N/A	-60	-54	-53	N/A
6/30/2025	1	-65	-58	-57	N/A
3/31/2025	2	-59	-60	-59	N/A
12/31/2024	5	-54	-60	-59	N/A
9/30/2024	6	-63	-63	-62	N/A
6/30/2024	8	-58	-63	-62	N/A
3/31/2024	7	-59	-60	-60	N/A
12/31/2023	7	-62	-60	-59	N/A
9/30/2023	9	-60	-58	-57	N/A
6/30/2023	9	-62	-63	-62	N/A
3/31/2023	20	-50	-63	-62	N/A
12/31/2022	190	118	117	119	N/A
9/30/2022	189	117	112	114	N/A
6/30/2022	190	118	111	113	N/A
3/31/2022	182	106	101	102	N/A
12/31/2021	10	-64	-92	-91	N/A
9/30/2021	9	-67	-71	-69	N/A
6/30/2021	6	-72	-55	-54	N/A
3/31/2021	7	-66	-47	-46	N/A
12/31/2020	9	-63	-31	-29	N/A
9/30/2020	11	-53	-47	-45	N/A
6/30/2020	14	-48	-58	-56	N/A
3/31/2020	17	-43	-30	-28	N/A
12/31/2019	20	-36	N/A	-1	N/A
9/30/2019	17	-37	N/A	1	N/A
6/30/2019	14	-38	N/A	4	N/A
3/31/2019	12	-38	N/A	-19	N/A
12/31/2018	10	-37	N/A	-42	N/A
9/30/2018	17	-27	N/A	-41	N/A
6/30/2018	23	-18	N/A	-39	N/A
3/31/2018	22	-24	N/A	N/A	N/A
12/31/2017	20	-25	N/A	-40	N/A
9/30/2017	17	-26	N/A	N/A	N/A
6/30/2017	16	-28	N/A	-38	N/A
3/31/2017	19	-22	N/A	N/A	N/A
12/31/2016	23	-19	N/A	-35	N/A
9/30/2016	27	-13	N/A	N/A	N/A
6/30/2016	31	-3	N/A	18	N/A
3/31/2016	30	-2	N/A	N/A	N/A
12/31/2015	29	0	N/A	26	N/A
9/30/2015	28	-6	N/A	N/A	N/A
6/30/2015	25	-11	N/A	-24	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MOLN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: MOLN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: MOLN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: MOLN şirketinin gelirinin (yıllık 49% ) Swiss pazarından (yıllık 4.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MOLN şirketinin gelirinin (yıllık 49% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MOLN 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 48.2 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/26 23:10
Gün Sonu Hisse Fiyatı	2026/05/26 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Molecular Partners AG 7 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Robert Burns	H.C. Wainwright & Co.
Richard Vosser	J.P. Morgan
Wei Chang	Leerink Partners LLC

Molecular Partners Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 12% to CHF10.33

Price target increased by 12% to CHF10.50

Price target increased by 7.2% to CHF10.03

Consensus revenue estimates fall by 33%

Consensus EPS estimates upgraded to CHF1.53 loss

Consensus revenue estimates decrease by 62%, EPS upgraded

Recent updates

High number of new directors

Molecular Partners Presents Three Posters At AACR 2026, with New Preclinical Data for First Switch-DARPin T Cell Engager MP0632 and DLL3 Radio-DARPin MP0712

Molecular Partners AG Announces Board and Committee Appointments

Molecular Partners Ag Announces That Current Board Member Steven H. Holtzman Will Not Stand for Re-Election

Molecular Partners AG, Annual General Meeting, Apr 14, 2026

Molecular Partners AG Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability To Multiple Isotopes

New major risk - Share price stability

Molecular Partners AG to Report First Half, 2026 Results on Aug 25, 2026

Price target increased by 12% to CHF10.33

Molecular Partners AG Announces Formation of Scientific Advisory Board for Radiopharmaceuticals

Molecular Partners AG Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025

First half 2025 earnings released: CHF1.02 loss per share (vs CHF0.80 loss in 1H 2024)

New major risk - Revenue size

Molecular Partners AG to Report Fiscal Year 2025 Results on Mar 12, 2026

Molecular Partners AG Announces Appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer and Member of Executive Committee, Effective October 1, 2025

Molecular Partners and Orano Med Present Preclinical Data on Mesothelin-Targeting Radio-DARPin Candidate MP0726 at SNMMI 2025

New major risk - Share price stability

Molecular Partners AG Presents Positive Data from Ongoing Phase 1/2a Trial of MP0533 in AML at EHA 2025

First quarter 2025 earnings released: CHF0.45 loss per share (vs CHF0.34 loss in 1Q 2024)

Molecular Partners AG Presents New Preclinical Data on Radio-DARPin and Switch-DARPin Programs at AACR 2025

Molecular Partners AG, Annual General Meeting, Apr 16, 2025

Price target increased by 12% to CHF10.50

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Price target increased by 7.2% to CHF10.03

Full year 2024 earnings released: CHF1.59 loss per share (vs CHF1.89 loss in FY 2023)

Molecular Partners AG to Report First Half, 2025 Results on Aug 25, 2025

Consensus revenue estimates fall by 33%

Molecular Partners AG to Report Q4, 2024 Results on Mar 07, 2025

Consensus EPS estimates upgraded to CHF1.53 loss

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Third quarter 2024 earnings released: CHF0.49 loss per share (vs CHF0.35 loss in 3Q 2023)

New minor risk - Shareholder dilution

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Consensus revenue estimates decrease by 62%, EPS upgraded

Second quarter 2024 earnings released: CHF0.46 loss per share (vs CHF0.49 loss in 2Q 2023)

Price target decreased by 9.7% to CHF9.35

Price target increased by 11% to CHF10.35

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

First quarter 2024 earnings released: CHF0.34 loss per share (vs CHF0.45 loss in 1Q 2023)

Insufficient new directors

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Consensus revenue estimates fall by 45%

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Full year 2023 earnings released: CHF1.89 loss per share (vs CHF3.63 profit in FY 2022)

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Consensus revenue estimates fall by 29%

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

New major risk - Share price stability

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Third quarter 2023 earnings released: CHF0.35 loss per share (vs CHF0.41 loss in 3Q 2022)

Consensus revenue estimates decrease by 40%

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Second quarter 2023 earnings released: CHF0.49 loss per share (vs CHF0.14 loss in 2Q 2022)

Molecular Partners AG Announces Executive Changes

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Consensus revenue estimates fall by 12%

First quarter 2023 earnings released: CHF0.45 loss per share (vs CHF4.74 profit in 1Q 2022)

Consensus revenue estimates decrease by 73%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Price target decreased to CHF12.87